AVEO Annual CFF
$82.90 M
+$30.65 M+58.65%
31 December 2021
Summary:
As of January 26, 2025, AVEO annual cash flow from financing activities is $82.90 million, with the most recent change of +$30.65 million (+58.65%) on December 31, 2021. During the last 3 years, it has risen by +$66.98 million (+420.59%).AVEO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVEO Quarterly CFF
$36.00 K
-$525.00 K-93.58%
30 September 2022
Summary:
As of January 26, 2025, AVEO quarterly cash flow from financing activities is $36.00 thousand, with the most recent change of -$525.00 thousand (-93.58%) on September 30, 2022. Over the past year, it has increased by +$826.00 thousand (+104.56%).AVEO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVEO TTM CFF
$6.12 M
+$826.00 K+15.60%
30 September 2022
Summary:
As of January 26, 2025, AVEO TTM cash flow from financing activities is $6.12 million, with the most recent change of +$826.00 thousand (+15.60%) on September 30, 2022. Over the past year, it has dropped by -$77.20 million (-92.65%).AVEO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVEO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.6% | +104.6% | -92.7% |
| 3 y3 years | +420.6% | +102.4% | -76.6% |
| 5 y5 years | +181.8% | -86.7% | -76.6% |
AVEO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -42.0% | -100.0% | -96.4% |
AVEO Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | $36.00 K(-93.6%) | $6.12 M(+15.6%) |
| June 2022 | - | $561.00 K(>+9900.0%) | $5.29 M(+7.7%) |
| Mar 2022 | - | $0.00(-100.0%) | $4.92 M(-94.1%) |
| Dec 2021 | $82.90 M(+58.7%) | $5.52 M(-799.2%) | $82.90 M(-0.5%) |
| Sept 2021 | - | -$790.00 K(-531.7%) | $83.32 M(-4.8%) |
| June 2021 | - | $183.00 K(-99.8%) | $87.48 M(-34.0%) |
| Mar 2021 | - | $77.99 M(+1213.6%) | $132.63 M(+153.8%) |
| Dec 2020 | $52.26 M(+99.5%) | $5.94 M(+75.8%) | $52.26 M(+19.5%) |
| Sept 2020 | - | $3.38 M(-92.5%) | $43.74 M(+12.5%) |
| June 2020 | - | $45.33 M(-1997.4%) | $38.86 M(+138.5%) |
| Mar 2020 | - | -$2.39 M(-7.4%) | $16.29 M(-37.8%) |
| Dec 2019 | $26.19 M(+64.5%) | -$2.58 M(+72.4%) | $26.19 M(-33.5%) |
| Sept 2019 | - | -$1.50 M(-106.6%) | $39.41 M(-14.4%) |
| June 2019 | - | $22.76 M(+203.0%) | $46.03 M(+96.4%) |
| Mar 2019 | - | $7.51 M(-29.4%) | $23.44 M(+47.2%) |
| Dec 2018 | $15.93 M(-45.9%) | $10.64 M(+107.5%) | $15.93 M(+206.7%) |
| Sept 2018 | - | $5.13 M(+2915.3%) | $5.19 M(+1440.7%) |
| June 2018 | - | $170.00 K(-2528.6%) | $337.00 K(-97.6%) |
| Mar 2018 | - | -$7000.00(-92.8%) | $13.94 M(-52.6%) |
| Dec 2017 | $29.42 M(+45.0%) | -$97.00 K(-135.8%) | $29.42 M(-0.3%) |
| Sept 2017 | - | $271.00 K(-98.0%) | $29.52 M(+1.0%) |
| June 2017 | - | $13.77 M(-11.0%) | $29.23 M(-18.3%) |
| Mar 2017 | - | $15.47 M(>+9900.0%) | $35.78 M(+76.3%) |
| Dec 2016 | $20.29 M(-1902.1%) | $1000.00(-107.1%) | $20.29 M(+18.1%) |
| Sept 2016 | - | -$14.00 K(-100.1%) | $17.19 M(-7.9%) |
| June 2016 | - | $20.32 M(<-9900.0%) | $18.66 M(-764.4%) |
| Mar 2016 | - | -$13.00 K(-99.6%) | -$2.81 M(+149.4%) |
| Dec 2015 | -$1.13 M | -$3.10 M(-313.2%) | -$1.13 M(-156.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | $1.46 M(-226.9%) | $1.98 M(-74.8%) |
| June 2015 | - | -$1.15 M(-168.7%) | $7.86 M(+51.7%) |
| Mar 2015 | - | $1.67 M(>+9900.0%) | $5.18 M(+409.0%) |
| Dec 2014 | $1.02 M(-97.8%) | $0.00(-100.0%) | $1.02 M(-175.6%) |
| Sept 2014 | - | $7.34 M(-291.8%) | -$1.35 M(-87.8%) |
| June 2014 | - | -$3.83 M(+53.4%) | -$11.03 M(+19.9%) |
| Mar 2014 | - | -$2.50 M(+5.5%) | -$9.21 M(-119.6%) |
| Dec 2013 | $47.00 M(+1398.7%) | -$2.36 M(+0.7%) | $47.00 M(-5.4%) |
| Sept 2013 | - | -$2.35 M(+17.4%) | $49.70 M(-5.3%) |
| June 2013 | - | -$2.00 M(-103.7%) | $52.50 M(-4.8%) |
| Mar 2013 | - | $53.71 M(>+9900.0%) | $55.16 M(+1659.0%) |
| Dec 2012 | $3.14 M(-97.3%) | $339.00 K(-25.0%) | $3.14 M(-9.3%) |
| Sept 2012 | - | $452.00 K(-31.7%) | $3.46 M(-9.8%) |
| June 2012 | - | $662.00 K(-60.7%) | $3.83 M(-96.7%) |
| Mar 2012 | - | $1.68 M(+155.0%) | $116.57 M(+1.0%) |
| Dec 2011 | $115.37 M(-19.2%) | $660.00 K(-20.3%) | $115.37 M(-33.0%) |
| Sept 2011 | - | $828.00 K(-99.3%) | $172.24 M(+0.4%) |
| June 2011 | - | $113.40 M(>+9900.0%) | $171.62 M(+136.5%) |
| Mar 2011 | - | $478.00 K(-99.2%) | $72.56 M(-49.2%) |
| Dec 2010 | $142.83 M(+360.2%) | $57.53 M(>+9900.0%) | $142.83 M(+68.8%) |
| Sept 2010 | - | $215.00 K(-98.5%) | $84.64 M(-11.2%) |
| June 2010 | - | $14.34 M(-79.7%) | $95.36 M(+18.6%) |
| Mar 2010 | - | $70.75 M(<-9900.0%) | $80.42 M(+159.1%) |
| Dec 2009 | $31.04 M(+351.0%) | -$667.00 K(-106.1%) | $31.04 M(-2.1%) |
| Sept 2009 | - | $10.94 M(-1911.6%) | $31.70 M(+52.7%) |
| June 2009 | - | -$604.00 K(-102.8%) | $20.76 M(-2.8%) |
| Mar 2009 | - | $21.36 M | $21.36 M |
| Dec 2008 | $6.88 M(-87.0%) | - | - |
| Dec 2007 | $52.83 M | - | - |
FAQ
- What is AVEO Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for AVEO Pharmaceuticals?
- What is AVEO Pharmaceuticals annual CFF year-on-year change?
- What is AVEO Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for AVEO Pharmaceuticals?
- What is AVEO Pharmaceuticals quarterly CFF year-on-year change?
- What is AVEO Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for AVEO Pharmaceuticals?
- What is AVEO Pharmaceuticals TTM CFF year-on-year change?
What is AVEO Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of AVEO is $82.90 M
What is the all time high annual CFF for AVEO Pharmaceuticals?
AVEO Pharmaceuticals all-time high annual cash flow from financing activities is $142.83 M
What is AVEO Pharmaceuticals annual CFF year-on-year change?
Over the past year, AVEO annual cash flow from financing activities has changed by +$30.65 M (+58.65%)
What is AVEO Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of AVEO is $36.00 K
What is the all time high quarterly CFF for AVEO Pharmaceuticals?
AVEO Pharmaceuticals all-time high quarterly cash flow from financing activities is $113.40 M
What is AVEO Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, AVEO quarterly cash flow from financing activities has changed by +$826.00 K (+104.56%)
What is AVEO Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of AVEO is $6.12 M
What is the all time high TTM CFF for AVEO Pharmaceuticals?
AVEO Pharmaceuticals all-time high TTM cash flow from financing activities is $172.24 M
What is AVEO Pharmaceuticals TTM CFF year-on-year change?
Over the past year, AVEO TTM cash flow from financing activities has changed by -$77.20 M (-92.65%)